You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
GenPro will use its EpiMarker machine-learning platform to identify a network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of drug response.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.
BostonGene will analyze the tumors of patients enrolled in NEC or NEC-affiliated clinical trials and NEC will use the data to help improve treatment responses.
The partners will use ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.
Through the public-private consortium of companies and institutions across Asia and Austria, the company aims to advance biomarker-driven cancer research.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
The alliance will join Sanofi's oncology pipeline with MD Anderson's premier clinical trials infrastructure to identify new biomarkers and streamline patient selection.
The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab.
Thermo Fisher has also applied to the Japanese Ministry of Health, Labor, and Welfare to expand the use of the Oncomine Dx Target test in Japan.
Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.